SCHEMBL2500364

SCHEMBL2500364

C1=N[N]c2ccccc2C1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
NPC1 O15118 4/20 0.33
RAB9A P51151 4/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 1/20 0.33
TRPA1 O75762 1/20 0.33
ACHE P22303 5/20 0.32
BCHE P06276 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
POLB P06746 1/20 0.32
USP2 O75604 1/20 0.32
LMNA P02545 1/20 0.32
CYP3A4 P08684 1/20 0.32
TSHR P16473 1/20 0.31
HPGD P15428 2/20 0.30
OPRM1 P35372 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL60763 0.75
SCHEMBL29861109 0.75
Ammonia Solution, Strong SCHEMBL23326973 0.73 TRPA1 (0.43) NOS3NOS1NOS2NPC1RAB9A
Bromide SCHEMBL30657202 0.73 TRPA1 (0.43) NOS3NOS1NOS2NPC1RAB9A
Iodide SCHEMBL29564978 0.73 TRPA1 (0.43) NOS3NOS1NOS2NPC1RAB9A
Bromide SCHEMBL30099792 0.73 TRPA1 (0.43) NOS3NOS1NOS2NPC1RAB9A
SCHEMBL29940088 0.73 TRPA1 (0.43) NOS3NOS1NOS2NPC1RAB9A
Iodide SCHEMBL16149430 0.73 TRPA1 (0.43) NOS3NOS1NOS2NPC1RAB9A
Hydrochloric Acid SCHEMBL7530965 0.73 TRPA1 (0.43) NOS3NOS1NOS2NPC1RAB9A
Hydrochloric Acid SCHEMBL29459702 0.73 TRPA1 (0.43) NOS3NOS1NOS2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110245156-A1 NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE CYTOKINE PHARMASCIENCES, INC. (US) 2011-10-06 US claimed
US-20110245156-A1 NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE CYTOKINE PHARMASCIENCES, INC. (US) 2011-10-06 US disclosed
US-20100234364-A1 CCR2 INHIBITORS AND METHODS OF USE THEREOF CHEMOCENTRYX, INC. 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234364-A1 CCR2 INHIBITORS AND METHODS OF USE THEREOF CCR2, CCR9, CCR1 NOS3 4123/4885NOS1 4477/4885NOS2 3568/4885
US-20110245156-A1 NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE DDX5, SAMHD1, EIF2AK2 NOS3 3235/4885NOS1 3990/4885NOS2 3804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.